The European Medicines Agency (EMA) draft policy on “publication and access to clinical-trial data” could pave the way to a new era in the disclosure of clinical data on medicines.
Attachment: sept2013_ema_transparencypolicy.pdf
The European Medicines Agency (EMA) draft policy on “publication and access to clinical-trial data” could pave the way to a new era in the disclosure of clinical data on medicines.
Attachment: sept2013_ema_transparencypolicy.pdf